About me

Dr. Martin-Subero graduated from the University of Navarra (Spain) with a degree in Biochemistry. In 2001, he completed a PhD with honours as a joined effort between the University of Navarra and the Christian-Albrechts University of Kiel (Germany). He continued his postdoctoral training at the Christian-Albrechts University. Upon returning to Spain in 2009, he started to coordinate a research group on epigenomics at the University of Barcelona. In 2016, he was appointed leader of the Biomedical Epigenomics group at the IDIBAPS research institute in Barcelona, and in 2018 he was awarded with an ICREA Research Professorship. He has published over 200 peer-reviewed articles.

Featured publications

Featured Projects

  • Single-cell genomics to comprehensively understand healthy B-cell maturation and transformation in Chronic Lymphocytic Leukemia (BCLLatlas)

    Principal investigator: José Ignacio Martín Subero
    Funder: Eurpean Research Council (ERC)
    Code: H2020-ERC-SyG-2019 (810287)
    Duration: 01/04/2019 - 31/03/2024
  • Early detection and intervention: Understanding the mechanisms of transformation and hidden resistance of incurable haematological malignancies

    Principal investigator: José Ignacio Martín Subero
    Funder: Asociación Española Contra el Cáncer (AECC)
    Code: AECC_Accelerator Award 2017
    Duration: 01/12/2018 - 30/11/2023
  • Análisis a escala genómica de la estructura de la cromatina en el linfoma de las células del manto: impacto biológico y clínico (ChromMCL)

    Principal investigator: José Ignacio Martín Subero
    Code: SAF2017-86126-R
    Duration: 01/01/2018 - 31/12/2020
  • Biomedical epigenomics research group

    Principal investigator: José Ignacio Martín Subero
    Funder: Generalitat de Catalunya
    Code: AGAUR-SGR17-00736
    Duration: 01/01/2017 - 30/09/2021
  • Deciphering the pathogenetic and clinical role of aberrant DNA methylation of enhancer elements in chronic lymphocytic leukemia

    Principal investigator: José Ignacio Martín Subero
    Funder: World Cancer Research Fund International
    Code: 16-1285
    Duration: 01/07/2016 - 30/06/2019